Variant position: 165 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 210 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human INKQTPNKQIWLSSPSSGPK RYDW----TGKNWVYSHDGVSLHEL
Mouse INKQTPNKQIWLSSPSSGPK RYDW----TGKNWVYSHDGVS
Rat INKQTPLLYLWFSGPCSGPK RYDW----TGKNWVYSHDGVS
Bovine INKQTPNKQIWLSSPSSGPK RYDW----TGRNWVYSHDGVS
Caenorhabditis elegans INKQSPNKQIWLSSPMSGPK RYDL---EEEGKWTYAHDGEQ
Drosophila INRQTPNKQIWLSSPTSGPK RYDFVGTVAAGRWIYKHSGQS
Slime mold INKQTPNRQIWWSSPLSGPK RFDY--DSVEKRWVDNRDGTP
Baker's yeast INKQPPNKQIWLASPLSGPN RFDL----LNGEWVSLRNGTK
Fission yeast INKQPPAHQIWLSSPVSGPK HYEY--SLKSKTWCSTRDEGT
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
42 – 210 Frataxin intermediate form
56 – 210 Frataxin(56-210)
78 – 210 Frataxin(78-210)
81 – 210 Frataxin mature form
161 – 210 SGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA -> RLTWLLWLFHP. In isoform 2.
161 – 210 SGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA -> RYVVDLSVMTGLGKTGCTPTTACPSMSCWPQSSLKP. In isoform 3.
164 – 168
The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene.
Forrest S.M.; Knight M.; Delatycki M.B.; Paris D.; Williamson R.; King J.; Yeung L.; Nassif N.; Nicholson G.A.;
Cited for: VARIANTS FRDA VAL-130; CYS-165 AND PHE-182;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.